Ceritinib dihydrochloride
CAS : 1380575-43-8
Ref. 3D-FFC57543
5mg | Arrêté | ||
10mg | Arrêté | ||
25mg | Arrêté | ||
50mg | Arrêté | ||
100mg | Arrêté |
Informations sur le produit
- 5-chloro-2-N-(5-methyl-4-piperidin-4-yl-2-propan-2-yloxyphenyl)-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine,dihydrochloride
- Cs-1407
- W-6134
- LDK-378 dihydrochloride
- 5-Chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine hydrochloride
- 5-Chloro-N2-(2-Isopropoxy-5-Methyl-4-(Piperidin-4-Yl)Phenyl)-N4-(2-(Isopropylsulfonyl)Phenyl)Pyrimidine-2,4-Diamine 2Hcl
- LDK378 2Hcl
- 5-chloro-N2-(2-isopropoxy-5-Methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyriMidine-2,4-diaMine hydrochloride
- 5-Chloro-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-N2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine hydrochloride (1:2)
Ceritinib dihydrochloride is a molecule that is used in the treatment of cancer. It inhibits tyrosine kinases, which are enzymes involved in cell signaling and growth. Ceritinib dihydrochloride has been shown to be effective against cancers that have developed resistance to other treatments, such as butyrate, chloroformate, nitro, and hydrochloric acid. It has been shown to inhibit the production of reactive oxygen species and tumor necrosis factor-α (TNF-α) in mouse models with lung cancer. The effective dose of ceritinib dihydrochloride is not yet known.